Effects of farnesoid X receptor activation on arachidonic acid metabolism, NF-kB signaling, and hepatic inflammation

Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects

Samuelsson, B. O., Dahlén, S., LINDGREN, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233 · see citing works

Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis

Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · see citing works

ARACHIDONIC ACID METABOLISM

Needleman, P., Truk, J., Jakschik, B. A., Morrison, A. R., & Lefkowith, J. B. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.000441 · Cited by 1,809 · see citing works

Epoxygenase Pathways of Arachidonic Acid Metabolism

Zeldin, D. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100030200 · Cited by 655 · see citing works

Action of epoxyeicosatrienoic acids on cellular function

Spector, A. A., & Norris, A. W. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00402.2006 · Cited by 480 · see citing works

Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil

Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407 · see citing works

BLT1 and BLT2: the leukotriene B4 receptors

Tager, A. M., & Luster, A. D. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00073-5 · Cited by 367 · see citing works

Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology

Imig, J. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00021.2011 · Cited by 363 · see citing works

Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease

Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger‐Moore, J., Jackson, J. P., Ferguson, S., & Cherrington, N. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027466 · Cited by 352 · see citing works

Lipid-Cytokine-Chemokine Cascade Drives Neutrophil Recruitment in a Murine Model of Inflammatory Arthritis

Chou, R. C., Kim, N. D., Sadik, C. D., Seung, E., Lan, Y., Byrne, M. H., Haribabu, B., Iwakura, Y., & Luster, A. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.07.018 · Cited by 342 · see citing works

LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes

Li, P., Oh, D. Y., Bandyopadhyay, G. K., Lagakos, W., Talukdar, S., Osborn, O., Johnson, A., Chung, H., Mayoral, R., Maris, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3800 · Cited by 318 · see citing works

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290 · see citing works

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236 · see citing works

Farnesoid X Receptor Modulates Renal Lipid Metabolism, Fibrosis, and Diabetic Nephropathy

Jiang, T., Wang, X. X., Scherzer, P., Wilson, P. V., Tallman, J., Takahashi, H., Li, J., Iwahashi, M., Sutherland, E. M., Arend, L. J., et al. (2007) · Diabetes · doi:10.2337/db06-1642 · Cited by 235 · see citing works

Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease

McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446575 · Cited by 225 · see citing works

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease

Hall, Z., Bond, N. J., Ashmore, T., Sanders, F., Ament, Z., Wang, X., Murray, A. J., Bellafante, E., Virtue, S., Vidal‐Puig, A., et al. (2016) · Hepatology · doi:10.1002/hep.28953 · Cited by 210 · see citing works

Role of Leukotriene B4Receptors in the Development of Atherosclerosis: Potential Mechanisms

Subbarao, K., Jala, V. R., Mathis, S., Suttles, J., Zacharias, W., Ahamed, J., Ali, H., Tseng, M. T., & Haribabu, B. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000110503.16605.15 · Cited by 209 · see citing works

Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation

Deng, Y., Theken, K. N., & Lee, C. R. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.10.022 · Cited by 194 · see citing works

The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase

Chacos, N., Capdevila, J. H., Falck, J. R., Manna, S., Martinwixtrom, C. A., Gill, S. S., Hammock, B. D., & Estabrook, R. W. (1983) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(83)90628-8 · Cited by 189 · see citing works

Deficiency of the Leukotriene B4 Receptor, BLT-1, Protects against Systemic Insulin Resistance in Diet-Induced Obesity

Spite, M. R., Hellmann, J. L., Tang, Y., Mathis, S., Kosuri, M., Bhatnagar, A., Jala, V. R., & Haribabu, B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100196 · Cited by 177 · see citing works

Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human Hepatocytes

Raucy, J. L., Mueller, L., Duan, K., Allen, S. W., Strom, S. C., & Lasker, J. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033837 · Cited by 146 · see citing works

Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance

Luria, A., Bettaieb, A., Xi, Y., Shieh, G.-J., Liu, H.-C., Inoue, H., Tsai, H.-J., Imig, J. D., Haj, F. G., & Hammock, B. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103482108 · Cited by 144 · see citing works

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

Wen, X., Wang, J. S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2001) · PubMed · Cited by 139 · see citing works

CytochromeP-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways

Yang, S., Lin, L., Chen, J.-X., Lee, C. R., Seubert, J. M., Wang, Y., Wang, H., Chao, Z.-R., Tao, D., Gong, J.-P., et al. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00783.2006 · Cited by 130 · see citing works

Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates Diet-induced Endoplasmic Reticulum Stress in Liver and Adipose Tissue

Bettaieb, A., Nagata, N., AbouBechara, D., Chahed, S. L., Morisseau, C. H. P., Hammock, B. D., & Haj, F. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.458414 · Cited by 124 · see citing works

High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation

Weiss, G. A., Troxler, H., Klinke, G., Rogler, D., Braegger, C., & Hersberger, M. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-89 · Cited by 120 · see citing works

5-Lipoxygenase Deficiency Reduces Hepatic Inflammation and Tumor Necrosis Factor α–Induced Hepatocyte Damage in Hyperlipidemia-Prone Apoe-Null Mice

Martínez‐Clemente, M., Ferré, N., González‐Périz, A., López‐Parra, M., Horrillo, R., Titos, E., Morán‐Salvador, E., Miquel, R., Arroyo, V., Funk, C. D., et al. (2009) · Hepatology · doi:10.1002/hep.23463 · Cited by 111 · see citing works

Increased CYP2J3 Expression Reduces Insulin Resistance in Fructose-Treated Rats and db/db Mice

Xu, X., Zhao, C. X., Wang, L., Tu, L., Fang, X., Zheng, C., Edin, M. L., Zeldin, D. C., & Wang, D. W. (2010) · Diabetes · doi:10.2337/db09-1241 · Cited by 107 · see citing works

Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE −/− Mice With Chronic Kidney Disease

Miyazaki‐Anzai, S., Levi, M., Kratzer, A., Ting, T. C., Lewis, L., & Miyazaki, M. (2010) · Circulation Research · doi:10.1161/circresaha.109.212969 · Cited by 101 · see citing works

[43] Cytochrome P-450 arachidonate oxygenase

Capdevila, J. H., Falck, J. R., Dishman, E., & Karara, A. (1990) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(90)87045-5 · Cited by 92 · see citing works

Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice

Gai, Z., Gui, T., Hiller, C., & Kullak-Ublick, G. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.694323 · Cited by 92 · see citing works

Epoxyeicosatrienoic Acids Regulate Macrophage Polarization and Prevent LPS‐Induced Cardiac Dysfunction

Dai, M., Wu, L., He, Z., Zhang, S., Chen, C., Xu, X., Wang, P., Gruzdev, A., Zeldin, D. C., & Wang, D. W. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24939 · Cited by 91 · see citing works

Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity

Zha, W., Edin, M. L., Vendrov, K. C., Schuck, R. N., Lih, F. B., Jat, J. L., Bradbury, J. A., DeGraff, L. M., Hua, K., Tomer, K. B., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053199 · Cited by 83 · see citing works

Adenosine2Areceptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway

Carroll, M. A., Doumad, A. B., Li, J., Cheng, M. K., Falck, J. R., & McGiff, J. C. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00231.2005 · Cited by 81 · see citing works

Effect of Chenodeoxycholic Acid on Fibrosis, Inflammation and Oxidative Stress in Kidney in High-Fructose-Fed Wistar Rats

Hu, Z., Ren, L., Wang, C., Liu, B., & Song, G. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000341485 · Cited by 68 · see citing works

CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ

Li, R., Xu, X., Chen, C., Wang, Y., Gruzdev, A., Zeldin, D. C., & Wang, D. W. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00118.2014 · Cited by 64 · see citing works

Benzoxathiole Derivative Blocks Lipopolysaccharide-Induced Nuclear Factor-κB Activation and Nuclear Factor-κB-Regulated Gene Transcription through Inactivating Inhibitory κB Kinase β

Kim, B. H., Roh, E., Lee, H. Y., Lee, I.-J., Ahn, B., Jung, S., Lee, H., Han, S., & Kim, Y. S. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.041251 · Cited by 62 · see citing works

EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels

Sodhi, K., Puri, N., Inoue, K., Falck, J. R., Schwartzman, M. L., & Abraham, N. G. (2011) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2011.12.004 · Cited by 57 · see citing works

An Algorithm that Predicts the Viability and the Yield of Human Hepatocytes Isolated from Remnant Liver Pieces Obtained from Liver Resections

Lee, S. M. L., Schelcher, C., Laubender, R. P., Fröse, N., Thasler, R., Schiergens, T. S., Mansmann, U., & Thasler, W. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107567 · Cited by 30 · see citing works

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002 · see citing works

Arachidonic Acid Metabolism and Kidney Inflammation

Wang, T., Fu, X., Chen, Q., Patra, J. K., Wang, D., Wang, Z., & Gai, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153683 · Cited by 435 · see citing works

Lipid Accumulation and Chronic Kidney Disease

Gai, Z., Wang, T., Visentin, M., Kullak-Ublick, G. A., Fu, X., & Wang, Z. (2019) · Nutrients · doi:10.3390/nu11040722 · Cited by 431 · see citing works

An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease

Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/4020249 · Cited by 209 · see citing works

Update on FXR Biology: Promising Therapeutic Target?

Han, C. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072069 · Cited by 185 · see citing works

Drugs and hepatic transporters: A review

Jetter, A., & Kullak-Ublick, G. A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.018 · Cited by 174 · see citing works

Bile acids and their receptors: modulators and therapeutic targets in liver inflammation

Bertolini, A., Fiorotto, R., & Strazzabosco, M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00935-7 · Cited by 142 · see citing works

The role of bile acids in cholestatic liver injury

Cai, S.-Y., & Boyer, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-5110 · Cited by 110 · see citing works

Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease

Jiao, T., Ma, Y., Guo, X., Ye, Y., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00880-z · Cited by 122 · see citing works

Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH

Cariello, M., Piccinin, E., & Moschetta, A. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.012 · Cited by 103 · see citing works

Versatile Triad Alliance: Bile Acid, Taurine and Microbiota

Duszka, K. (2022) · Cells · doi:10.3390/cells11152337 · Cited by 100 · see citing works

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

Abenavoli, L., Falalyeyeva, T. M., Boccuto, L., Tsyryuk, O., & Kobyliak, N. M. (2018) · Pharmaceuticals · doi:10.3390/ph11040104 · Cited by 89 · see citing works

CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators

Shi, Z., He, Z., & Wang, D. W. (2022) · Molecules · doi:10.3390/molecules27123873 · Cited by 82 · see citing works

Geniposide Ameliorates Liver Fibrosis Through Reducing Oxidative Stress and Inflammatory Respose, Inhibiting Apoptosis and Modulating Overall Metabolism

Yang, L., Bi, L., Jin, L., Wang, Y., Li, Y., Li, Z., He, W., Cui, H., Miao, J., & Wang, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772635 · Cited by 81 · see citing works

Effects of Exposure to Different Types of Metal–Organic Framework Nanoparticles on the Gut Microbiota and Liver Metabolism of Adult Zebrafish

Yang, L., Chen, H., Kaziem, A. E., Miao, X., Huang, S.-Q., Cheng, D., Xu, H., & Zhang, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c03451 · Cited by 74 · see citing works

Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications

Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 75 · see citing works

The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism

Shu, Y., Huang, Y., Dong, W., Fan, X., Sun, Y., Chen, G., Zeng, X., & Ye, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125662 · Cited by 70 · see citing works

Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis

Schumacher, J. D., & Guo, G. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_228 · Cited by 64 · see citing works

Activation of Farnesoid X Receptor by Schaftoside Ameliorates Acetaminophen-Induced Hepatotoxicity by Modulating Oxidative Stress and Inflammation

Liu, M., Zhang, G., Song, M., Wang, J., Shen, C., Chen, Z., Huang, X., Gao, Y., Zhu, C., Lin, C., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7791 · Cited by 59 · see citing works

Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis

Venetsanaki, V., Karabouta, Z., & Polyzos, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172661 · Cited by 52 · see citing works

Depletion of Gut Microbiota Inhibits Hepatic Lipid Accumulation in High-Fat Diet-Fed Mice

Han, H. L., Wang, M., Zhong, R., Yi, B., Schroyen, M., & Zhang, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169350 · Cited by 49 · see citing works

Mechanism of rutaecarpine on ethanol-induced acute gastric ulcer using integrated metabolomics and network pharmacology

Ren, S., Wei, Y., Niu, M., Li, R., Wang, R., Wei, S., Wen, J., Wang, D., Yang, T., Chen, X., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111490 · Cited by 46 · see citing works

Nuclear receptors in liver fibrosis

Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45 · see citing works

Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress

Gai, Z., Krajnc, E., Samodelov, S. L., Visentin, M., & Kullak-Ublick, G. A. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118646 · Cited by 44 · see citing works

Nonalcoholic fatty liver disease and portal hypertension

Ryou, M. K., Stylopoulos, N., & Baffy, G. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00011 · Cited by 43 · see citing works

Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis

Wang, D., Li, R., Wei, S., Gao, S., Xu, Z., Liu, H., Wang, R., Li, H., Cai, H., Wang, J., et al. (2019) · Chinese Medicine · doi:10.1186/s13020-019-0251-z · Cited by 41 · see citing works

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity

Rausch, M., Samodelov, S. L., Visentin, M., & Kullak-Ublick, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213967 · Cited by 40 · see citing works

HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism

Chiu, A. P., Tschida, B. R., Sham, T.-T., Lo, L. H., Moriarity, B. S., Li, X., Lo, R. C., Hinton, D. E., Rowlands, D. K., Chan, C.-O., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1127 · Cited by 38 · see citing works

Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD

Zhang, P., Wang, W., Mao, M., Gao, R., Shi, W., Li, D., Calderone, R., Sui, B., Tian, X., & Meng, X. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.710285 · Cited by 35 · see citing works

FXR and NASH: an avenue for tissue-specific regulation

Henry, Z. R., Meadows, V., & Guo, G. L. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000127 · Cited by 35 · see citing works

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases

Meadows, V., Kennedy, L. L., Kundu, D., Alpini, G. D., & Francis, H. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00015 · Cited by 31 · see citing works

Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor

Tang, K., Kong, D., Peng, Y., Guo, J., Zhong, Y., Yu, H., Mai, Z., Chen, Y., Chen, Y., Cui, T., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1000444 · Cited by 33 · see citing works

Farnesoid X receptor activation induces the degradation of hepatotoxic 1‐deoxysphingolipids in non‐alcoholic fatty liver disease

Gai, Z., Gui, T., Alecu, I., Lone, M. A., Hornemann, T., Chen, Q., Visentin, M., Hiller, C., Häusler, S., & Kullak-Ublick, G. A. (2019) · Liver International · doi:10.1111/liv.14340 · Cited by 31 · see citing works

Epoxyeicosatrienoic Acids and Fibrosis: Recent Insights for the Novel Therapeutic Strategies

Guan, X., Rao, D., Liu, Y.-Z., Zhou, Y., & Yang, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910714 · Cited by 31 · see citing works

A network pharmacology approach: Inhibition of the NF-κB signaling pathway contributes to the NASH preventative effect of an Oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats

Sun, W., Liu, P., Wang, M., Wang, T., Wang, T., Sun, W., Song, X., Zheng, W., Song, X., & Li, J. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153498 · Cited by 29 · see citing works

Vascular targets for the treatment of portal hypertension

Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1693115 · Cited by 28 · see citing works

Improving fatty liver hemorrhagic syndrome in laying hens through gut microbiota and oxylipin metabolism by Bacteroides fragilis: A potential involvement of arachidonic acid

Zhang, S., You, M., Shen, Y.-M., Zhao, X.-H., He, X., Liu, J., & Ma, N. (2024) · Animal Nutrition · doi:10.1016/j.aninu.2024.08.008 · Cited by 30 · see citing works

PE_PGRS: Vital proteins in promoting mycobacterial survival and modulating host immunity and metabolism

Xie, Y., Zhou, Y., Liu, S., & Zhang, X. (2020) · Cellular Microbiology · doi:10.1111/cmi.13290 · Cited by 25 · see citing works

Hepatic SIRT6 Modulates Transcriptional Activities of FXR to Alleviate Acetaminophen-induced Hepatotoxicity

Liu, C., Pan, Z., Wu, Z.-L., Tang, K., Zhong, Y., Chen, Y., Xiao, X., Guo, J., Duan, S., Cui, T., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.04.011 · Cited by 25 · see citing works

Eight Zhes Decoction ameliorates the lipid dysfunction of nonalcoholic fatty liver disease using integrated lipidomics, network pharmacology and pharmacokinetics

Zhou, Y., Dai, Z., Deng, K., Wang, Y., Ying, J., Chu, D., Zhou, J., & Tang, C. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.05.012 · Cited by 24 · see citing works

Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease

Yin, H., Shi, A., & Wu, J. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s367483 · Cited by 22 · see citing works

Understanding the Effects of Metabolites on the Gut Microbiome and Severe Acute Pancreatitis

Ye, S., Si, C., Deng, J., Chen, X., Kong, L., Zhou, X., & Wang, W. (2021) · BioMed Research International · doi:10.1155/2021/1516855 · Cited by 21 · see citing works

Targeting nuclear receptors for NASH/MASH: From bench to bedside

Sinha, R. A. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.002 · Cited by 18 · see citing works

Role of Bile Acid Receptors in the Development and Function of Diabetic Nephropathy

Fang, Y., Qin, M., Zheng, Q., Wang, K., Han, X., Yang, Q., Sang, X., & Cao, G. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.08.002 · Cited by 22 · see citing works

NF-κB signaling and crosstalk during carcinogenesis

Brücher, B. L. D. M., Lang, F. J. W., & Jamall, I. S. (2019) · 4open · doi:10.1051/fopen/2019010 · Cited by 21 · see citing works

The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney disease

Masaoutis, C., & Theocharis, S. (2018) · Expert opinion on therapeutic targets · doi:10.1080/14728222.2019.1559825 · Cited by 16 · see citing works

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

Schierle, S., Helmstädter, M., Schmidt, J., Hartmann, M., Horz, M., Kaiser, A., Weizel, L., Heitel, P., Proschak, A., Hernández‐Olmos, V., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900576 · Cited by 19 · see citing works

Target lipidomics approach to reveal the resolution of inflammation induced by Chinese medicine combination in Liu-Shen-Wan against realgar overexposure to rats

Wang, J., Ding, L., Zhou, J., Ma, H., Wu, Y., Wang, J., Lv, X., Liu, S., Wang, H., Yan, Y., et al. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112171 · Cited by 18 · see citing works

Integrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis

Zhang, K., Yuan, Y., Dawa, Z., Liu, F., Yao, Y., Wang, M., Zhu, C., & Lin, C. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115268 · Cited by 16 · see citing works

Farnesoid X receptor regulates PI3K/AKT/mTOR signaling pathway, lipid metabolism, and immune response in hybrid grouper

Xu, J., Yao, X., Li, X., Xie, S., Chi, S., Zhang, S., Cao, J., & Tan, B. (2022) · Fish Physiology and Biochemistry · doi:10.1007/s10695-022-01130-z · Cited by 16 · see citing works

Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy

Li, C., Li, Y., & Gai, Z. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190726152847 · Cited by 16 · see citing works

Regulation of the cytochrome P450 epoxyeicosanoid pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease

Kalveram, L., Schunck, W., Rothe, M., Rudolph, B. D., Loddenkemper, C., Holzhütter, H., Henning, S., Bufler, P., Schulz, M., Meierhofer, D., et al. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102229 · Cited by 16 · see citing works

Comparison of Erythrocyte Membrane Lipid Profiles between NAFLD Patients with or without Hyperlipidemia

Chen, W., Shao, S., Cai, H., Han, J., Guo, T., Fu, Y., Yu, C., Zhao, M., Bo, T., Yao, Z., et al. (2020) · International Journal of Endocrinology · doi:10.1155/2020/9501826 · Cited by 15 · see citing works

Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p

Li, C., Zhang, S., Chen, X., Ji, J., Yang, W., Gui, T., Gai, Z., & Li, Y. (2020) · Communications Biology · doi:10.1038/s42003-020-1058-2 · Cited by 15 · see citing works

The metabolic benefits of substituting sucrose for maple syrup are associated with a shift in carbohydrate digestion and gut microbiota composition in high-fat high-sucrose diet-fed mice

Morissette, A., André, D. M., Agrinier, A.-L., Varin, T. V., Pilon, G., Flamand, N., Houde, V. P., & Marette, A. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00065.2023 · Cited by 14 · see citing works

Knockout of farnesoid X receptor aggravates process of diabetic cardiomyopathy

Qiang, S., Tao, L., Zhou, J., Wang, Q., Wang, K., Lü, M., Wang, W.-F., Lin, H., Xue, S., Chen, Y., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108033 · Cited by 13 · see citing works

Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease

Pan, Q., Fan, J., & Yilmaz, Y. N. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.013 · Cited by 12 · see citing works

Farnesoid X receptor regulates lung macrophage activation and injury following nitrogen mustard exposure

Murray, A., Banota, T., Guo, G. L., Smith, L. C., Meshanni, J. A., Lee, J. M., Kong, B., Абрамова, Е. В., Goedken, M. J., Gow, A. J., et al. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116208 · Cited by 12 · see citing works

Probiotic Bacillus cereus regulates metabolic disorders and activates the cholic acid-FXR axis to alleviate DSS-induced colitis

Liao, Y., Wu, S., Zhou, G., Mei, S., Ou, B., Wen, M., Yang, Y., & Wen, G. (2024) · Journal of Proteomics · doi:10.1016/j.jprot.2024.105360 · Cited by 11 · see citing works

Slow-Release H2S Donor Anethole Dithiolethione Protects Liver From Lipotoxicity by Improving Fatty Acid Metabolism

Zhao, C., Yu, N., Li, W., Cai, H., Liu, M., Hu, Y., Liu, Y., & Tang, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.549377 · Cited by 11 · see citing works

Untargeted serum metabolites profiling in high-fat diet mice supplemented with enhanced palm tocotrienol-rich fraction using UHPLC-MS

Goon, D. E., Rahim, S. A., Sakri, A. H. M., Mazlan, M., Tan, J. K., Aziz, M. A., Noor, N. M., Ibrahim, E., & Kadir, S. H. S. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-00454-9 · Cited by 11 · see citing works

Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets

Wu, D., & van de Graaf, S. F. J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116437 · Cited by 10 · see citing works

Obeticholic Acid—A Pharmacological and Clinical Review

Keshvani, C., Kopel, J. J., & Goyal, H. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010017 · Cited by 10 · see citing works

Fiber consumption stimulates the activity of microbial bile salt hydrolases

Gregor, A., Auernigg‐Haselmaier, S., Malleier, M., Bruckberger, S., Séneca, J., Pjevac, P., Pignitter, M., & Duszka, K. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105707 · Cited by 10 · see citing works

FXR Friend-ChIPs in the Enterohepatic System

Meadows, V., Yang, Z., Basaly, V., & Guo, G. L. (2023) · Seminars in Liver Disease · doi:10.1055/a-2128-5538 · Cited by 8 · see citing works

Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders

Girisa, S., Aswani, B., Manickasamy, M., Hegde, M., Alqahtani, M., Abbas, M., Sethi, G., & Kunnumakkara, A. (2025) · Expert opinion on therapeutic targets · doi:10.1080/14728222.2025.2487465 · Cited by 8 · see citing works

Systematic Analysis of the Pharmacological Effects of Alcoholic Components in Maotai

Zhou, W., Chen, Z., Bao, H., Zhang, G., & Liu, Z. (2019) · Journal of Food Science · doi:10.1111/1750-3841.14656 · Cited by 8 · see citing works

Relationship between hepatic lipid accumulation and type 2 diabetes mellitus

Wang, Z., Zan, W., Fan, Z., & Wang, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118723 · Cited by 8 · see citing works

1,25-dihydroxyvitamin D3 improves non-alcoholic steatohepatitis phenotype in a diet-induced rat model

Liu, M., Song, X.-Z., Yang, L., Fang, Y.-H., Lan, L., Cui, J.-S., Lu, X.-C., Zhu, H.-Y., Quan, L.-H., & Han, H.-M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1528768 · Cited by 6 · see citing works

Herpetrione alleviates ANIT-induced cholestatic liver injury by targeting FXR to suppress NF-κB signaling.

Jing, L., Liao, Y., Zhan, H.-H., Chen, Q., Wei, X., Qiu, Y.-D., Meng, F.-C., Liao, Z.-H., & Chen, M. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120839 · Cited by 7 · see citing works

Structural characterization and therapeutic effect of Alhagi honey oligosaccharide on liver fibrosis in mice

Lv, Z., Song, J., Xiang, Y., Chen, Z., Lu, Z., Zhou, Q., Wang, K., Dahong, H. T., Zheng, J., Zhang, C., et al. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105974 · Cited by 6 · see citing works

Research progress on the hepatoprotective effect, pharmacokinetic properties, and hepatotoxicity of geniposide

Tang, S., Yan, G., Kong, L. D., Sun, H. J., Liu, C., Han, Y. M., & Wang, X. (2025) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000160 · Cited by 6 · see citing works

Dual soluble epoxide hydrolase inhibitor – farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis

Khan, A. H., Nolan, B., Stavniichuk, A., Merk, D., & Imig, J. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269261 · Cited by 5 · see citing works

Farnesoid X Receptor (FXR) Agonists and Protein Kinase Regulation in NAFLD and NASH: Mechanisms and Therapeutic Potential

Saha, A., Wood, E., Omeragic, L., Minkara, M., Marma, K., Gupta, S. D., & Ferdoush, J. (2025) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases3030016 · Cited by 4 · see citing works

Duchesnea indica Extract Ameliorates LPS-Induced Septic Shock in Mice

Lee, Y. Y., Yuk, H. J., Saba, E., Kim, S., Kim, D.-S., Kopalli, S. R., Oh, J., & Rhee, M. H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5783867 · Cited by 4 · see citing works

Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats

Shen, Y., Liu, J., Yao, B., Zhang, Y., Huang, S., Liang, C., Huang, J., Tang, Y., & Wang, X. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.04.010 · Cited by 4 · see citing works

Metabolome combined with gut microbiome revealed the lipid-lowering mechanism of Xuezhiping capsule on hyperlipidemic hamster induced by high fat diet

Wang, L., Zhang, Z., Luo, G., Wang, Y., Du, K., & Gao, X. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1147910 · Cited by 4 · see citing works

Transformations in plasma metabolic profiles of patients with major depression disorder during treatment

Du, Y., Li, X., Zhang, S. Y., Tan, J., Zhu, Y., Zhai, X., & Lu, Y. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01682-y · Cited by 2 · see citing works

Metabolomics study on the therapeutic mechanism of Schisandra chinensis polysaccharides on concanavalin A-induced immunological liver injury in mice

Sun, J., Chen, L., Shan, Y., Wang, C., Li, H., & Chen, J. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_255_20 · Cited by 2 · see citing works

Methods and tools used to describe and quantify the associations between diet, inflammation, and health

Hébert, J. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822130-3.00005-3 · Cited by 2 · see citing works

Mechanism of Red Yeast Rice in the Improvement of Atherosclerosis in Apolipoprotein E-deficient Mice Explored Through Metabolomics Combined with Serum Pharmacochemistry and Network Pharmacology

Zhang, Y., Ren, D., Liu, Y., Li, N., Yang, X., Yang, S., & Liu, R. (2025) · Plant Foods for Human Nutrition · doi:10.1007/s11130-025-01379-8 · Cited by 1 · see citing works

TGR5 and FXR receptors in motor degeneration: Molecular mechanism, crosstalk pathways and therapeutic prospects

Banerjee, S., Panjwani, D., Singh, S., & Singh, T. G. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.578942 · Cited by 1 · see citing works

Sinomenine alleviates ulcerative colitis by targeting FXR to regulate arachidonic acid metabolism and Th17/Treg homeostasis

Li, M., Chen, D., Shao, Y., Wang, Z., Peng, Y., Zhao, Q., & Liu, L. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178976 · Cited by 1 · see citing works

Inflammation in the long arc of history

Hébert, J. R., & Hofseth, L. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822130-3.00012-0 · Cited by 1 · see citing works

Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators

Lamers, C., & Merk, D. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00076 · Cited by 1 · see citing works

Bile Acids and Bilirubin in Liver Immunology

Zhu, C., Claudel, T., & Trauner, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_7

Study on the Protective Effect and the Metabolomics Features of Rutaecarpine on Ethanol-induced Acute Gastric UlcerPreprint

Ren, S., Wei, Y. L., Niu, M., Wang, R., Wei, S., Wen, J., Wang, D., Yang, T., Chen, X., Wu, S., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-48441/v1

Non-Targeted Cellular Metabolomics Revealing the Metabolomic Features and Anti-Tumor Mechanisms of Cyanidin-3-O-Arabinoside from Apple on CaCo-2 CellsPreprint

Xu, G. Z., Xue, W., Zhang, D., Yu, Z., Liu, J., & Zhao, W. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4174081

Alleviation of Type 2 Diabetes Mellitus by Bai-Hu-Jia-Ren-Shen Decoction Through Modulating Serum Metabolism

Pan, B., Yao, B., Hou, M., Liu, C., Su, X., Zhang, S., Li, Y., Zhang, H., Li, W., Lv, S., et al. (2024) · Journal of Biobased Materials and Bioenergy · doi:10.1166/jbmb.2024.2423

Macronutrient-differential dietary pattern impacts on body weight, hepatic inflammation, and metabolism

Li, Y., Madduri, S. S., Rezeli, E. T., Santos, C., Freeman, H., Peng, J., McRitchie, S., Pathmasiri, W., Hursting, S. D., Sumner, S., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1356038

The effects of farnesoid X receptor activation on arachidonic acid metabolism, NF-kB signaling and hepatic inflammation

Gai, Z., Visentin, M., Gui, T., Zhao, L., Thasler, W., Hausler, S., Hartling, I., Cremonesi, A., Hiller, C., & Kullak-Ublick, G. A. (2018) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-151937

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice

Lin, C., Yu, B., Chen, L., Zhang, Z., Ye, W., Zhong, H., Bai, W., Yang, Y., & Nie, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.880508 · Cited by 17 · see citing works

Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.

Xu, J.-Y., Li, Z.-P., Zhang, L., & Ji, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13493 · Cited by 37 · see citing works

Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease

Xu, S., Kong, L., Li, L., Wang, C., Gu, J., Luo, H., & Meng, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166930 · Cited by 10 · see citing works

FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation

Yao, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14430 · Cited by 78 · see citing works